Are there any agents being developed specifically for visceral pain

Are there any agents being developed specifically for visceral pain?

Linaclotide, a guanylate cyclase inhibitor, and lubiprostone, a chloride channel activator, have demonstrated analgesic efficacy in both animal models of visceral pain and patients with constipation-predominant irritable bowel syndrome. In humans, the analgesic efficacy of these drugs is closely tied to their promotility effects. Serotonin receptor subtype 3 (5HT3R) antagonists, like alosetron, have similar visceral analgesic effects; however, severe restrictions have been placed on its use due to adverse effects of ischemic colitis. Eluxadoline, a mixed agonist/antagonist at mu-, delta-, and kappa-opioid receptors, has recently been demonstrated to be effective for both pain and diarrhea in patients with IBS diarrhea-predominant subtypes. P2X purinoreceptor 3 antagonists are undergoing animal studies. The P2X3 receptor functions as a ligand-gated ion channel that may transduce ATP-evoked nociceptor activation, thought to be involved in visceral pain mediation. Antagonism results in pain relief in mouse models of visceral pain.


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information